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The role of bilirubin to albumin ratio as a predictor 
for mortality in critically ill patients without existing 
liver or biliary tract disease
Background: Hyperbilirubinemia and hypoalbuminemia are frequently appeared and associ-
ated with poor prognosis in critically ill patients. We aim to evaluate the association between 
the bilirubin to albumin ratio and prognosis in intensive care unit (ICU) patients.
Methods: This was a retrospective study of 731 patients who were admitted to the medical 
intensive care unit (MICU) at a tertiary-care center from July 2015 to September 2017. We 
analyzed the bilirubin to albumin ratio on admission to the MICU, including clinical charac-
teristics and other examinations.
Results: The overall 28-day survival of MICU patients was 69.1%. On univariate analysis, Acute 
Physiology and Chronic Health Evaluation (APACHE) II score (P<0.001), Sequential Organ 
Failure Assessment score (P<0.001), Simplified Acute Physiology Score II score (P<0.001), C-
reactive protein (P=0.015), and bilirubin/albumin ratio (P<0.001) were associated with mor-
tality of ICU patients. The receiver operating characteristic curves for ICU patients mortality 
between bilirubin to albumin ratio and APACHE II score were not statistically significant 
(P=0.282). On multivariate analysis, higher APACHE II score (hazard ratio [HR], 1.05; 95% CI, 
1.03 to 1.06; P<0.001) and bilirubin to albumin ratio (HR, 1.65; 95% CI, 1.23 to 2.20; P=0.001) 
were independently related to the ICU patient mortality.
Conclusions: A higher bilirubin to albumin ratio was related to the unfavorable prognosis 
and mortality in critically ill patients.
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INTRODUCTION
Hepatic response plays an crucial role in the host defense mechanisms in sepsis or other critical 
illness patients [1-3]. Hepatic dysfunction is indicative of poor outcomes in critically ill patients 
[4], and abnormal liver function test, including elevated alanine aminotransferase (ALT), and 
aspartate aminotransferase (AST), alkaline phosphatase, and bilirubin, are traditionally pre-
sented in critically ill patients [5]. Hepatic dysfunction, particularly manifested as hyperbilirubi-
nemia, is associated with poor outcomes [6,7]. Widely used scoring systems for sepsis, such as 
Sequential (sepsis-related) Organ Failure Assessment (SOFA) score and Simplified Acute Physi-
ology Score (SAPS), included bilirubin level to estimate the hepatic dysfunction [8,9]. Low albu-
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min level is also helpful for predicting the poor prognosis in 
acutely ill patients [4,10]. Because of its importance for predict-
ing the outcome in ICU patients, serum albumin level has in-
cluded in the Acute Physiology and Chronic Health Evaluation 
(APACHE) III score [11]. 
 Several studies of the relationship between serum bilirubin 
to albumin ratio (B/A ratio) and patient prognosis have been 
conducted [12,13]. In neonates, the B/A ratio can be used to 
predict acute bilirubin-induced neurologic dysfunction [12,13]. 
However, there is no prior research about the relationship be-
tween the B/A ratio and prognosis in critically ill elderly patients. 
Therefore, we aim to evaluate if there is a relationship between 
the B/A ratio and higher mortality in critically ill patients.
MATERIALS AND METHODS
Patients and Study Design
This was a retrospective cohort study of patients who admitted 
to the medical intensive care unit (MICU) at a tertiary-care uni-
versity hospital in South Korea between July, 1, 2015 and Sep-
tember, 30, 2017. The medical ICU is a 30-bed closed unit where 
is managed by certified ICU specialists. A total of 867 patients 
were admitted to our MICU during study period. Among them, 
136 patients who had the acute toxic or alcoholic hepatitis, chro-
nic hepatitis, liver cirrhosis, cholecystitis with or without chol-
angitis, and those who had liver, biliary, or pancreatic surgery 
were excluded. A total of 731 patients were enrolled to this study 
(Figure 1). 
 The protocol was approved by institutional review board (IRB 
No. 4-2016-0951). The need for informed consent was waived 
given the retrospective nature of the study. 
KEY MESSAGES 
■  Hepatic dysfunction is related to worse outcomes in crit-
ically ill patients.
■  The purpose of this study is to analyze the role of the bili-
rubin to albumin ratio as a prognostic factor in critically 
ill patients.
Data Collection 
The laboratory findings with serum bilirubin and albumin con-
centrations, including patients’ baseline characteristics, disease 
severity such as APACHE II and SOFA scoring system, were re-
viewed to analyze the relevance to mortality in ICU patients. 
The laboratory tests used in this study conducted within 24 
hours from admission of ICU, and disease severities were evalu-
ated on ICU admission. The primary outcome was 28-day all-
cause mortality.
Statistical Analysis
The categorical variables are presented as absolute frequency 
and percentages, and the continuous variables are presented as 
mean ±standard deviation. The clinical characteristics of the 
two groups, survivors and non-survivors, were compared using 
the Pearson’s chi-squared test or Fisher’s exact test for categori-
cal variables and Student’s t-test for continuous variables. Uni-
variate logistic regression analysis was performed first, and 
P<0.05 was considered statistically significant [14,15]. Multivar-
iate analysis was performed using the forward stepwise data se-
lection method [14,15]. Cutoff values of 0.05 and 0.1 were used 
to either enter or remove a covariate into or from the final mod-
el, and the results are described as odds ratio (ORs) with their 
95% confidence intervals (CIs). Cox proportional-hazard re-
gression analysis was used to evaluate the association between 
variables and mortality. The effect of age, sex, body mass index 
(BMI) and APACHE II score was evaluated using Cox propor-
tional-hazard models, with an adjusted P-value <0.05 consid-
ered statistically significant. The hazard ratios and 95% CIs were 
calculated. Survival was estimated using the Kaplan–Meier meth-
od, and differences in survival between groups were assessed 
using the log-rank test. Anaylsis of receiver operating character-
istic (ROC) curves and the area under the ROC curves (AUC) 
was performed to evaluate the predictive value of the B/A ratio 
and APACHE II score for mortality in critically ill patients. In ad-
dition, we compared the ROC curves between B/A ratio and 
APACHE II score. Kaplan-Meier analysis was used to evaluate 
the primary outcomes and P-values <0.05 were considered sta-
tistically significant. All statistical analyses were performed us-
Figure 1. Flowchart of inclusion and exclusion process for patient 
enrollment. A total of 867 patients were enrolled, and 731 patients 
were included in the analysis. ICU: intensive care unit.
867 Total patients (>19 yr) admitted to 
medical ICU
(Jul 2015 to Sep 2017)
731 Patients analyzed
505 Survivors 226 Non-survivor
136 Toxic or alcoholic  
hepatitis, chronic hepatitis, 
liver cirrhosis, cholecystitis,  
biliary tract surgery
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ing IBM SPSS ver. 23.0 (IBM Corp., Armonk, NY, USA) and 
MedCalc Statistical Software version 12.7.7 (MedCalc Software, 
Ostend, Belgium).








Age (yr) 65.6±15.2 67.9±13.1  0.043 
Male sex 311 (61.6) 137 (60.6)  0.805
BMI (kg/m2) 22.5±8.2 22.1±5.1  0.470 
Disease severity
   APACHE II score 21.6±9.9  27.5±10.5 <0.001
   SOFA score  7.7±3.9 10.6±4.0 <0.001
   SAPS II score (n=484)  37.9±16.3  50.5±19.3 <0.001
Underlying disease
Diabetes mellitus 189 (37.4)  73 (32.3)  0.182 
Chronic lung diseasea  89 (17.6)  35 (15.5)  0.477 
Hypertension 281 (55.6) 121 (53.5)  0.597 
Heart failureb  58 (11.5) 21 (9.3)  0.377 
Coronary artery disease  61 (12.1)  39 (17.3)  0.060 
Cancer 117 (23.2)  75 (33.2)  0.004 
Acute renal failurec 124 (24.6)  76 (33.6)  0.011 
ARDSd 43 (8.5)  28 (12.4)  0.102 
Laboratory parameter
WBC (103/µl)  14.2±11.2  15.1±11.8  0.888 
Hct (%) 29.7±6.5 28.0±7.0  0.002 
Platelet (103/mm3)  181.8±116.9  135.3±118.5 <0.001
Creatinine (mg/dl)  2.7±16.7  1.9±1.7  0.457 
Total bilirubin (mg/dl)  1.2±2.6  1.8±2.7  0.007 
Albumin (g/dl)  2.6±0.5  2.4±0.6 <0.001
CRP (mg/dl)  114.5±106.7  135.3±106.9  0.015 
Procalcitonin (ng/ml)  12.5±28.9  13.2±30.1  0.781 
Bilirubin/albumin ratio  0.4±0.9  0.7±1.0 <0.001
Values are presented as mean±standard deviation or number (%).
ICU, intensive care unit; BMI: body mass index; APACHE: Acute Physiol-
ogy and Chronic Health Evaluation; SOFA: Sequential Organ Failure As-
sessment; SAPS: Simplified Acute Physiology Score; ARDS: acute respi-
ratory distress syndrome; WBC: white blood cell; Hct: hematocrit; CRP: 
C-reactive protein.
aChronic lung disease includes asthma, chronic obstructive pulmonary 
disease, and structural lung diseases, such as bronchiectasis and inter-
stitial lung disease; bA complex clinical syndrome that results from any 
structural or functional impairment of ventricular filling or ejection of 
blood; cAn increase over 1.5 times or 0.3 mg/dl in serum creatinine with-
in 7 days compared to baseline or a urine output less than 0.5 ml/kg/hr 
during 6 to 12 hours according to the Kidney Disease: Improving Global 
Outcomes guidelines; dThe rapid onset of hypoxemia and pulmonary 
edema with diffuse bilateral pulmonary infiltrates from pulmonary or 
non-pulmonary disease when the PaO2/FiO2 ratio was less than 300 mm 
Hg at the time of ICU admission.
Table 2. Multivariate analysis to predict 28-day mortality in ICU
Variable OR 95% CI P-value
Age 1.00 0.99–1.01 0.489
Sex 
   Male Reference Reference Reference
   Female 1.20 0.84–1.68 0.309
BMI 0.98 0.95–1.00 0.202
APACHE II score 1.06 1.04–1.07 <0.001
Underlying disease
Cancer 1.70 1.18–2.43 0.004
Bilirubin/albumin 1.27 1.07–1.51 0.006
ICU: intensive care unit; OR: odds ratio; CI: confidence interval; BMI: body 
mass index; APACHE: Acute Physiology and Chronic Health Evaluation.
RESULTS
Among a total of 867 patients who admitted to the medical ICU 
at our university hospital in Korea, 136 patients who had the 
acute toxic or alcoholic hepatitis, chronic hepatitis, liver cirrho-
sis, cholecystitis with or without cholangitis, and those who un-
derwent liver, biliary tract, or pancreatic surgery were excluded. 
Therefore, 731 patients were finally enrolled in our study; 448 
(61.3%) were men and 283 (38.7%) were women (Figure 1). The 
mean age was 66.4±14.7 years. The most common underlying 
disease was hypertension (n=402, 55.0%), followed by diabetes 
mellitus (n=262, 35.8%), solid cancers (n=192, 26.3%), and he-
matologic malignancies (n =45, 6.2%). The mean APACHE II 
score, SOFA score, and SAPSII were 23.5 ±10.5, 8.6 ±4.1, and 
41.8±17.2, respectively. In total, 470 patients (64.3%) were intu-
bated for acute respiratory failure. The overall 28-day survival of 
MICU patients was 69.1% (n=505); these patients were defined 
as survivors, and the remaining patients (n=226, 30.9%) were 
defined as non-survivors. Table 1. showed the comparison of 
baseline characteristics, clinical, and laboratory parameters be-
tween survival and non-survivors. On univariate analysis, age 
(P =0.043) and APACHE II score (P <0.001) were significantly 
higher in non-survivors. And, the incidence of cancer (P=0.004) 
and acute renal failure (P=0.011) was higher in non-survivors. 
Serum hematocrit (P=0.002), platelet (P<0.001), and albumin 
(P<0.001) were significantly lower in non-survivors than in sur-
vivors. Total bilirubin (P=0.007), C-reactive protein (P=0.015), 
and bilirubin/albumin ratio (P<0.001) were positively associat-
ed with mortality of ICU patients (Table 1). 
 The B/A ratio was significantly associated with 28-day mor-
tality in patients with admission in ICU on multivariate analysis 
adjusted for age, sex, BMI, underlying disease, and APACHE II 
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score (OR, 1.27; 95% CI, 1.07 to 1.51, P=0.006) (Table 2). Figure 
2 shows the ROC curves for bilirubin, B/A ratio and APACHE II 
score, and the AUC was 0.599, 0.628 and 0.666 for mortality in 
ICU patients. The ROC curves between B/A ratio and APACHE 
II score were not significantly different (P=0.282). The sensitivi-
ty and specificity for 28-day mortality were 58.4% and 64.2% at a 
B/A ratio cutoff of 0.31. 
 The Table 3 and Figure 3 represent the results of survival anal-
ysis. A higher B/A ratio (>0.31) was significantly correlated with 
lower 28-day mortality rates on Kaplan-Meier survival analysis 
(P <0.001) (Figure 3). The effect of age, sex, BMI, APACHE II 
score, underlying disease, and B/A ratio for 28-day mortality 
was investigated using the Cox proportional hazard model (Ta-
ble 3). For Kaplan-Meier survival analysis, patients were sepa-
rated into two groups according to B/A ratios at a cutoff value of 
0.31. The relative risk of mortality was significantly associated 
with B/A ratio (hazard ratio [HR], 1.65; 95% confidence interval 
[CI], 1.23 to 2.20; P=0.001). 
DISCUSSION
In this study, we found that initial B/A ratio was significantly as-
sociated with higher 28-day mortality in ICU patients. Based on 
ROC curve analysis, a B/A ratio cutoff values of 0.31 was identi-
fied for predicting the 28-day mortality. The large number of 
patients in our study could strength to the relevance of the re-
sults. These results strengthen our knowledge about the role of 
B/A ratio as a predictive factor for poor outcomes in critically ill 
patients.  
 Several previous reports about the mechanisms underlying 
liver dysfunction and jaundice in critical illnesses have been 
published. The liver is involved in host defense mechanisms 
and tissue repair facilitated by cross-talk and interactions among 
hepatic cell including hepatocytes, Kupffer cells, and endotheli-
al sinusoidal cells in patients with sepsis and other critical ill-
nesses [1]. However, over-activation of the systemic response, 
hypoxemia, and unexpected side effects of treatment could re-
sult in hepatic dysfunction [2]. The incidence of hepatic dys-
function resulting to abnormal liver test was reported in 10-30% 
of ICU patients [5,6,16].
 Liver function test abnormalities were commonly appeared 















Figure 2. Receiver operating characteristic (ROC) curve of serum 
bilirubin, bilirubin/albumin ratio, and Acute Physiology and Chron-
ic Health Evaluation (APACHE) II score curves as predictors of 28-
day mortality. The area under curve for the bilirubin/albumin ratio 
is not significantly inferior to APACHE II score (P=0.282).
Table 3. Cox proportional-hazard regression analysis
Variable HR 95% CI P-value
Age 0.99 0.98–1.01 0.632 
Sex
   Male Reference Reference Reference
   Female 1.22 0.93–1.60 0.150 
BMI 0.98 0.96–1.01 0.147 
APACHE II score 1.05 1.03–1.06 <0.001
Underlying disease
Cancer 1.41 1.07–1.86 0.015 
Bilirubin/albumin
   Low (≤0.31) Reference Reference Reference
   High (>0.31) 1.65 1.23–2.20 0.001 
HR: hazard ratio; CI: confidence interval; BMI: body mass index; APACHE: 
Acute Physiology and Chronic Health Evaluation.
Figure 3. Kaplan-Meier analysis of time to death in intensive care 
unit (ICU) patients according to bilirubin to albumin (B/A) ratio ≤0.31 
or >0.31 (P<0.001). 
0 5 10 15 20 25 30
Day after ICU admission
Number at risk
B/A ratio ≤0.31 416 392 381 364 351 335 307
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in critically ill patients from the two major pathogenesis: hypox-
ic hepatitis and cholestasis caused by critical illness [17]. An ini-
tial and disruptive increase of the liver lysis enzymes, including 
ALT and AST, in hypoxic hepatitis or shock liver was reflected 
diffuse hepatic injury as a result from the failure of oxygen deliv-
ery and ischemia in the liver from severe shock. [18,19]. Accord-
ing to a previous report, jaundice could develop in one-third of 
patients with hypoxic hepatitis [20]. Cholestasis followed by 
critical illness is more frequently manifested in the ICU and is 
characterized by mild abnormalities in hepatic function test 
with mainly cholestatic features. Hypoxic hepatitis is apparently 
associated with severe shock and liver hypoxia. However, it 
seems that cholestasis caused by critical illness are represented 
by cellular alterations from inflammation leading to a transient 
bile acid accumulation in the liver and systemic circulation, un-
like hypoxic hepatitis is associated with severe shock and liver 
hypoxia [6,20,21].
 Serum bilirubin concentration is usually conducted to evalu-
ated the liver function in ICU patients. Increased liver lysis en-
zymes are common in all cases that altered tissue perfusion oc-
cur. In addition, coagulation tests including prothrombin time 
and partial thromboplatin time are easily affected in many dis-
eases with coagulopathy, such as disseminated intravascular 
coagulation. On the other hand, serum bilirubin is easily mea-
sured and obtained. Therefore, the bilirubin levels were includ-
ed in already used organ dysfunction scoring system, such as 
SOFA [22], SAPS [9], and Logistic Organ Dysfunction Score [23].
 As a marker of liver dysfunction, elevation of bilirubin level 
has been considered to be directly related to prognosis in criti-
cally ill patients. Brienza et al. [5] found that the prevalence of 
hyperbilirubinemia with definition of that value more than 2 
mg/dL was 30% in critically ill patient. In their study, sepsis, se-
vere septic shock, mechanical ventilation with Positive End Ex-
piratory Pressure, and major surgery were risk factors for hyper-
bilirubinemia [5]. Recently, Pierrakos et al. [7] reported that hy-
perbilirubinemia without primary cause could be an indepen-
dent risk factor of mortality in ICU patient. In that study, the re-
lationship between bilirubin and mortality presented a linear 
correlation from the value of 1 to 6 mg/dl. [7]. In our study, se-
rum bilirubin level at ICU admission was a predictor for 28-day 
mortality. The results of our study were reliable to previous re-
ports. In fact, in general, not only a marker of liver dysfunction, 
bilirubin can itself affect results. In the previous reports, the 
bactericidal characters of neutrophils could be impaired by an-
tioxidative effects of bilirubin [24]. Furthermore, bilirubin can 
have nephrotoxic [25] and neurotoxic [26] effects. In addition, it 
can inhibit induced nitric oxide synthase [27] and exert platelet 
anti-aggregation effects, possible by inhibiting platelet activa-
tion induced from collagen [28]. Because we analyzed bilirubin 
levels relatively early on (at ICU admission), the toxicity of bili-
rubin itself may have affected mortality in this study.
 In addition, hypoalbuminemia is frequently appeared in crit-
ically ill patients, and lower serum albumin was associated with 
the higher mortality in acute ill patients [4,10]. In prior meta-
analysis of 90 cohort studies, lower serum albumin level was a 
dose-dependent prognostic factor for poor outcome including 
mortality, morbidity, and prolonged stay in ICU and hospital 
[4]. The relationship between hypoalbuminemia and worse 
outcome seemed to be independent from inflammation and 
nutritional status in this study [4]. In a prospective cohort study 
conducted in a single center ICU, APACHE II and albumin were 
associated with poor outcome and mortality independently in 
critically ill patients with severe sepsis or septic shock [10]. Be-
cause of its value as an prognostic factor for mortality, serum al-
bumin level was included to one of the component parameters 
in APACHE III score [11]. 
 In this study, we analyzed B/A ratio for predictor of mortality. 
In the previous reports, serum B/A ratio was expected as a pre-
dictor of bilirubin encephalopathy and neurologic dysfunction 
in neonates [12,29,30]. Free bilirubin, that is not bound to albu-
min, can pass by the blood-brain-barrier and appear a neuro-
toxicity [12,29,30]. The B/A ratio, which can be a substitute for 
free bilirubin, is considered to be a good additional parameter 
for total serum bilirubin, indicating an higher risk of bilirubin-
induced neurotoxicity in preterm infants [12,29,30]. However, 
the role of B/A ratio as a predictor for mortality in critically ill 
patient has not been evaluated before. In this study, the AUC of 
the B/A ratio was significantly higher than that of bilirubin and 
was not inferior to that of APACHE II score. A higher B/A ratio at 
ICU admission was associated with unfavorable outcomes in 
critically ill patients.
 This is the first study to investigate the role of B/A ratio in pre-
dicting the prognosis of critically ill adult patients in the ICU. Al-
though there are several scoring systems for predicting the mor-
tality in patients with critically illness, our study result of B/A ra-
tio is valuable in that it can be measured simply and easy to use 
everywhere. Furthermore, the predictive quality of the B/A ratio 
is not inferior to APACHE II score. 
 Nevertheless, our study has some limitations. First, this study 
result may be difficult to generalize because of a single-center 
retrospective observational study. Second, we were unable to 
measure urine output before admission to the ICU. Third, we 
could not assess changes in bilirubin, albumin, and B/A ratios, 
because serum albumin and bilirubin level were only collected 
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at first day of ICU admission. So, it is needed in the future to fur-
ther studies which investigate about the changes in those mark-
ers.
 The results of this study had showed that a higher B/A ratio 
might be related to higher mortality and worse outcome in criti-
cally ill patients. Hence, clinicians can use the initial measure-
ment of B/A ratio to predict the prognosis of ICU patients. Multi-
center studies with large samples need to be conducted for vali-
dation of these results and presenting the serum B/A ratio as a 
valuable marker for prediction of prognosis in critically ill pa-
tients.
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